At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Shingrix®biological
Likely dose
Shingrix® 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Systems Biology of Zoster Vaccine Recombinant, Adjuvanted (SHINGRIX)
In Brief
A Phase 2 clinical trial evaluating Shingrix® for Zoster and 3 related conditions. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsZoster, Zoster Varicella, Shingles, Chicken Pox
CountriesUnited States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartNov 2019
Primary CompletionApr 2023
Study CompletionOct 2023
TodayJul 2026
First PostedAug 7, 2019
Enrollment StartNov 14, 2019
Primary CompletionApr 3, 2023
Study CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.9 years ago
Interventions
Shingrix®biological
A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.